Drugs / genetically modified NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00995137 | Oct 2009 → May 2013 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | genetically modified NK cells | “Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.” NCT00995137 ↗ |
| Modality | Cell therapy | “genetically modified natural killer (NK) cells” NCT00995137 ↗ |
| Target | CD19 | “redirect NK cells towards CD19, a molecule highly expressed on the surface of B-lineage ALL cells” NCT00995137 ↗ |